North America Sleep Disorder Treatment Market - Industry Trends and Forecast to 2028
- Published Date: 2022-12-31
- Report ID: 143968
- Pages: 225
-
Format:
Short Description
North America Sleep Disorder Treatment Market, By Type (Insomnia, Sleep Apnea, Restless Legs Syndrome (RLS), Narcolepsy, and Others), Treatment (Pharmacological Therapy, Mechanical Therapy, Mandibular Advancement Devices, Hypoglossal Nerve Stimulator, Surgery, and Others), Route of Administration (Oral, Parenteral, and Others), Drugs Type (Branded and Generics), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, Ambulatory Surgical Center, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S, Canada and Mexico) Industry Trends and Forecast to 2028
Market Definition:
Sleep disorder such as sleep apnea, narcolepsy or insomnia are medical disorder in which the patient has difficulty with maintenance of sleep or sleep initiation. This disorder causes irregular mental, physical, social and emotional functions. Sleep disorders are treated via different treatment options according to the symptoms of the patients. Most of the sleep apnea patients are treated via mechanical therapies. Pharmacological therapies such as antidepressants, cannabidiols, benzodiazepines and stimulants are used for the treatment of insomnia, narcolepsy and restless legs syndrome among others. The intraoral devices are also used to prevent snoring by creating airway channel in order to create room for proper gas exchange.
Market Segmentation:
North America sleep disorder treatment market is categorized into seven notable segments which are based on basis of type, treatment, route of administration, drugs type, population type, end user and distribution channel.
On the basis of type, the sleep disorder treatment market is segmented into insomnia, sleep apnea, restless legs syndrome (RLS), narcolepsy and others
On the basis of treatment, the sleep disorder treatment market is segmented into pharmacological therapy, mechanical therapy, mandibular advancement devices, hypoglossal nerve stimulator, surgery and others
On the basis of route of administration, the sleep disorder treatment market is segmented into oral, parenteral and others
On the basis of drugs type, the sleep disorder treatment market is segmented into branded and generics
On the basis of population type, the sleep disorder treatment market is segmented into children and adults
On the basis of end user, the sleep disorder treatment market is segmented into hospitals, specialty clinics, home healthcare, ambulatory surgical center and others
On the basis of distribution channel, the sleep disorder treatment market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others
Market Players
The key market players for North America sleep disorder treatment market are listed below:
Jazz Pharmaceuticals, Inc.
Pfizer Inc.
Viatris Inc.
Arbor Pharmaceuticals
Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma)
sanofi-aventis U.S. LLC (a subsidiary of Sanofi)
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC
Lupin Pharmaceuticals, Inc. (a subsidiary of Lupin)
Taj Pharmaceuticals Limited
Eli Lilly and Company
Mallinckrodt
Alembic Pharmaceuticals Limited
Apotex Inc.
Dr. Reddys Laboratories Ltd.
Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
Taro Pharmaceutical Industries Ltd.
Koninklijke Philips N.V.
DeVilbiss Healthcare LLC
ResMed
SomnoMed
Oventus
BMC Medical Co.
TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET 17
1.4 CURRENCY AND PRICING 19
1.5 LIMITATIONS 20
1.6 MARKETS COVERED 20
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 25
2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.6 MULTIVARIATE MODELLING 30
2.7 TYPE LIFELINE CURVE 30
2.8 DBMR MARKET POSITION GRID 31
2.9 MARKET END USER COVERAGE GRID 33
2.10 SECONDARY SOURCES 34
2.11 ASSUMPTIONS 34
3 EXECUTIVE SUMMARY 35
4 PREMIUM INSIGHT 38
5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: REGULATIONS 39
6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS 41
7 MARKET OVERVIEW 42
7.1 DRIVERS 44
7.1.1 RISING PREVALENCE OF SLEEPING DISORDERS 44
7.1.2 RISE IN THE GERIATRIC POPULATION 45
7.1.3 INCREASE IN MENTAL STRESS DUE TO HECTIC LIFE & UNHEALTHY HABITS 46
7.1.4 LARGE POOL OF UNDIAGNOSED SLEEP APNEA PATIENTS 46
7.1.5 PRESENCE OF POTENTIAL CLINICAL PIPELINE CANDIDATES 47
7.2 RESTRAINTS 48
7.2.1 SIDE EFFECTS ASSOCIATED WITH THESE DRUGS 48
7.2.2 PATENT EXPIRATION OF MAJOR SLEEP DISORDER TREATMENT DRUGS 48
7.2.3 EMERGENCE OF GENERICS 48
7.3 OPPORTUNITIES 50
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE SLEEP AIDS IN THE U.S. 50
7.3.2 INCREASING USAGE OF SOCIAL MEDIA AND GROWING ADDICTION OF GADGETS SUCH AS SMARTPHONES AND LAPTOPS 50
7.3.3 GROWING AWARENESS ABOUT TARGET DISEASE 52
7.4 CHALLENGES 53
7.4.1 HIGH COST OF DIAGNOSIS & TREATMENT FOR SLEEPING DISORDER 53
7.4.2 STRINGENT REGULATORY LANDSCAPE 53
7.4.3 POTENTIAL ILL-EFFECTS DUE TO DRUG ABUSE 54
8 IMPACT OF COVID-19 ON NORTH AMERICA SLEEP DISORDER TREATMENT MARKET 55
8.1 PRICE IMPACT 55
8.2 IMPACT ON DEMAND 56
8.3 IMPACT ON SUPPLY CHAIN 56
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19 56
8.5 CONCLUSION 57
9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE 58
9.1 OVERVIEW 59
9.2 INSOMNIA 62
9.2.1 INSOMNIA 62
9.2.2 CHILD INSOMNIA 62
9.2.3 OTHERS 62
9.3 SLEEP APNEA 63
9.3.1 OBSTRUCTIVE SLEEP APNEA 63
9.3.2 CENTRAL SLEEP APNEA 63
9.3.3 SNORING 63
9.3.4 INFANT SLEEP APNEA 64
9.3.5 OTHERS 64
9.4 RESTLESS LEGS SYNDROME (RLS) 64
9.5 NARCOLEPSY 64
9.5.1 TYPE 1 65
9.5.2 TYPE 2 65
10 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 66
10.1 OVERVIEW 67
10.2 PHARMACOLOGICAL THERAPY 70
10.2.1 CANNABIDIOL 71
10.2.2 ANTI-PARKINSONIAN DRUGS (DOPAMINE AGONISTS) 71
10.2.3 BENZODIAZEPINES 71
10.2.4 NON-BENZODIAZEPINE 71
10.2.5 MELATONIN RECEPTOR STIMULATOR 71
10.2.6 STIMULANTS 71
10.2.7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) 71
10.2.8 TRICYCLIC ANTIDEPRESSANTS 71
10.2.9 SODIUM OXYBATE (XYREM) 71
10.2.10 OTHERS 72
10.3 MECHANICAL THERAPY 72
10.3.1 CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE) 72
10.3.2 BI-LEVEL PAP 72
10.3.3 AUTO CPAP OR AUTO BI-LEVEL PAP 73
10.3.4 ADAPTIVE SERVO-VENTILATION (ASV) 73
10.4 MANDIBULAR ADVANCEMENT DEVICES 73
10.5 HYPOGLOSSAL NERVE STIMULATOR 73
10.6 SURGERY 74
10.6.1 SOMNOPLASTY 74
10.6.2 TONSILLECTOMY 74
10.6.3 NASAL SURGERY 74
10.6.4 OTHERS 75
10.7 OTHERS 75
11 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 76
11.1 OVERVIEW 77
11.2 ORAL 80
11.2.1 TABLET 80
11.2.2 PILLS 80
11.2.3 OTHERS 80
11.3 PARENTERAL 81
11.4 OTHERS 81
12 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 82
12.1 OVERVIEW 83
12.2 GENERICS 86
12.3 BRANDED 86
12.3.1 XYREM 87
12.3.2 EFFEXOR XR 87
12.3.3 AMBIEN 87
12.3.4 PRISTIQ 87
12.3.5 ZENZEDI 87
12.3.6 VYVANSE 87
12.3.7 OTHERS 88
13 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 89
13.1 OVERVIEW 90
13.2 ADULT 93
13.3 CHILDREN 93
14 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER 94
14.1 OVERVIEW 95
14.2 HOSPITALS 98
14.3 SPECIALTY CLINICS 98
14.4 HOME HEALTHCARE 98
14.5 AMBULATORY SURGICAL CENTER 99
14.6 OTHERS 99
15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 100
15.1 OVERVIEW 101
15.2 DIRECT TENDER 104
15.3 HOSPITAL PHARMACY 104
15.4 RETAIL PHARMACY 104
15.5 ONLINE PHARMACY 105
15.6 OTHERS 105
16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY REGION 106
16.1 NORTH AMERICA 107
16.1.1 U.S. 115
16.1.2 CANADA 120
16.1.3 MEXICO 125
17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY LANDSCAPE 130
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 130
18 SWOT ANALYSIS 131
19 COMPANY PROFILE 132
19.1 JAZZ PHARMACEUTICALS, INC. 132
19.1.1 COMPANY SNAPSHOT 132
19.1.2 REVENUE ANALYSIS 132
19.1.3 PRODUCT PORTFOLIO 133
19.1.4 RECENT DEVELOPMENTS 133
19.2 PFIZER INC. 134
19.2.1 COMPANY SNAPSHOT 134
19.2.2 REVENUE ANALYSIS 134
19.2.3 PRODUCT PORTFOLIO 135
19.2.4 RECENT DEVELOPMENT 135
19.3 ELI LILLY AND COMPANY 136
19.3.1 COMPANY SNAPSHOT 136
19.3.2 REVENUE ANALYSIS 136
19.3.3 COMPANY SHARE ANALYSIS 137
19.3.4 PRODUCT PORTFOLIO 137
19.3.5 RECENT DEVELOPMENTS 137
19.4 VIATRIS INC. 138
19.4.1 COMPANY SNAPSHOT 138
19.4.2 REVENUE ANALYSIS 138
19.4.3 COMPANY SHARE ANALYSIS 139
19.4.4 PRODUCT PORTFOLIO 139
19.4.5 RECENT DEVELOPMENTS 139
19.5 RESMED 140
19.5.1 COMPANY SNAPSHOT 140
19.5.2 REVENUE ANALYSIS 140
19.5.3 PRODUCT PORTFOLIO 141
19.5.4 RECENT DEVELOPMENTS 141
19.6 MALLINCKRODT 142
19.6.1 COMPANY SNAPSHOT 142
19.6.2 REVENUE ANALYSIS 142
19.6.3 PRODUCT PORTFOLIO 143
19.6.4 RECENT DEVELOPMENT 143
19.7 KONINKLIJKE PHILIPS N.V. 144
19.7.1 COMPANY SNAPSHOT 144
19.7.2 REVENUE ANALYSIS 144
19.7.3 PRODUCT PORTFOLIO 145
19.7.4 RECENT DEVELOPMENTS 146
19.8 ALEMBIC PHARMACEUTICALS LIMITED 147
19.8.1 COMPANY SNAPSHOT 147
19.8.2 REVENUE ANALYSIS 147
19.8.3 PRODUCT PORTFOLIO 148
19.8.4 RECENT DEVELOPMENT 148
19.9 AMNEAL PHARMACEUTICALS LLC 149
19.9.1 COMPANY SNAPSHOT 149
19.9.2 REVENUE ANALYSIS 149
19.9.3 PRODUCT PORTFOLIO 150
19.9.4 RECENT DEVELOPMENTS 150
19.10 APOTEX INC. 151
19.10.1 COMPANY SNAPSHOT 151
19.10.2 PRODUCT PORTFOLIO 151
19.10.3 RECENT DEVELOPMENT 151
19.11 ARBOR PHARMACEUTICALS 152
19.11.1 COMPANY SNAPSHOT 152
19.11.2 PRODUCT PORTFOLIO 152
19.11.3 RECENT DEVELOPMENTS 152
19.12 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA) 153
19.12.1 COMPANY SNAPSHOT 153
19.12.2 REVENUE ANALYSIS 153
19.12.3 PRODUCT PORTFOLIO 154
19.12.4 RECENT DEVELOPMENTS 154
19.13 BMC MEDICAL CO. 155
19.13.1 COMPANY SNAPSHOT 155
19.13.2 PRODUCT PORTFOLIO 155
19.13.3 RECENT DEVELOPMENT 156
19.14 DEVILBISS HEALTHCARE LLC 157
19.14.1 COMPANY SNAPSHOT 157
19.14.2 PRODUCT PORTFOLIO 157
19.15 DR. REDDYS LABORATORIES LTD. 159
19.15.1 COMPANY SNAPSHOT 159
19.15.2 REVENUE ANALYSIS 159
19.15.3 PRODUCT PORTFOLIO 160
19.15.4 RECENT DEVELOPMENT 160
19.16 HIKMA PHARMACEUTICALS PLC 161
19.16.1 COMPANY SNAPSHOT 161
19.16.2 REVENUE ANALYSIS 161
19.16.3 PRODUCT PORTFOLIO 162
19.16.4 RECENT DEVELOPMENTS 162
19.17 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN) 163
19.17.1 COMPANY SNAPSHOT 163
19.17.2 REVENUE ANALYSIS 163
19.17.3 PRODUCT PORTFOLIO 164
19.17.4 RECENT DEVELOPMENTS 164
19.18 OVENTUS 165
19.18.1 COMPANY SNAPSHOT 165
19.18.2 REVENUE ANALYSIS 165
19.18.3 PRODUCT PORTFOLIO 166
19.18.4 RECENT DEVELOPMENTS 166
19.19 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI) 167
19.19.1 COMPANY SNAPSHOT 167
19.19.2 REVENUE ANALYSIS 167
19.19.3 PRODUCT PORTFOLIO 168
19.19.4 RECENT DEVELOPMENTS 168
19.20 SOMNOMED 169
19.20.1 COMPANY SNAPSHOT 169
19.20.2 REVENUE ANALYSIS 169
19.20.3 PRODUCT PORTFOLIO 170
19.20.4 RECENT DEVELOPMENTS 170
19.21 TAJ PHARMACEUTICALS LIMITED 171
19.21.1 COMPANY SNAPSHOT 171
19.21.2 PRODUCT PORTFOLIO 171
19.21.3 RECENT DEVELOPMENT 171
19.22 TARO PHARMACEUTICAL INDUSTRIES LTD. 172
19.22.1 COMPANY SNAPSHOT 172
19.22.2 REVENUE ANALYSIS 172
19.22.3 PRODUCT PORTFOLIO 173
19.22.4 RECENT DEVELOPMENT 173
19.23 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 174
19.23.1 COMPANY SNAPSHOT 174
19.23.2 REVENUE ANALYSIS 174
19.23.3 PRODUCT PORTFOLIO 175
19.23.4 RECENT DEVELOPMENTS 175
20 QUESTIONNAIRE 176
21 RELATED REPORTS 180
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
